Inhibikase Therapeutics closed at $1.56 on Nov 4, up 5.74%, 37.9% below its 52-week closing high. Volume of 675.4K shares was 0.98× its 20-day average (close to normal).
Split-adjusted performance: -21.0% over one month, -22.1% over six months, -2.2% over one year.
Short interest was 19.6M shares at the Oct 15 settlement, up 1.0% from the prior report (17.8% of float, 31.1 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IKTInhibikase Therapeutics | $1.57 | +5.74% | −22.1% | — | — | — | $218.4M | |
| PALIPalisade Bio | $1.25 | +1.63% | −37.5% | — | −2114.8% | — | $217.8M | Compare |
| PLXProtalix BioTherapeutics | $2.69 | +3.07% | +33.2% | +27.1% | 19.0% | 11.4 | $216.7M | Compare |
| DTILPrecision BioSciences | $8.12 | +16.50% | +8.0% | −100.0% | — | — | $224.1M | Compare |
| ARTVArtiva Biotherapeutics | $4.22 | +0.48% | −65.9% | — | — | — | $206.3M | Compare |
| PROKProKidney | $1.12 | +4.67% | −42.9% | −32.1% | −18948.0% | — | $234.1M | Compare |
| CABACabaletta Bio | $1.42 | 0.00% | −61.9% | — | — | — | $240.8M | Compare |
| FATEFate Therapeutics | $2.09 | +2.45% | −8.7% | +9.2% | −1448.6% | — | $250.4M | Compare |
| ALECAlector | $2.28 | +11.22% | −11.3% | −57.8% | −692.5% | — | $254.6M | Compare |
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
